Open AccessIn vitro susceptibilities of common pediatric pathogens to LY163892
Author(s) -
Sharon Shelton,
John D. Nelson
Publication year - 1988
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.32.2.268
Subject(s) - cefaclor , amoxicillin , clavulanic acid , haemophilus influenzae , microbiology and biotechnology , moraxella (branhamella) catarrhalis , antibiotics , cephalosporin , antibacterial agent , beta lactamase , medicine , chemistry , moraxella catarrhalis , escherichia coli , biology , biochemistry , gene
LY163892 is a carbacephem antibiotic for oral administration with an antibacterial spectrum similar to that of cefaclor and amoxicillin-clavulanic acid. It has greater stability than cefaclor and greater activity against beta-lactamase-producing Haemophilus influenzae and Escherichia coli. LY163892 is less active than amoxicillin against streptococci and less active than amoxicillin-clavulanic acid against Branhamella catarrhalis but comparable against other pathogens.